Zhang Haiyan, Peng Wei, Zhang Yangde
National Hepatobiliary and Enteric Surgery Research Centre, Changsha, Hunan Province, China
National Hepatobiliary and Enteric Surgery Research Centre, Changsha, Hunan Province, China.
J Int Med Res. 2014 Jun;42(3):641-50. doi: 10.1177/0300060513506328. Epub 2014 Mar 20.
To investigate if the administration of neoadjuvant chemotherapy (NACT) reduces pelvic lymph node metastasis by inducing tumour cell apoptosis in patients with cervical cancer.
This study enrolled patients with stage Ib2-IIb cervical cancer who underwent surgery with (NACT group) or without (control group) prior cisplatin-based chemotherapy. Immunohistochemical staining of caspase-3 and an in situ terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labelling assay were used to measure the levels of apoptosis in primary tumours and pelvic lymph nodes.
A total of 185 patients participated in the study: 102 in the NACT group and 83 in the control group. Treatment was considered to be clinically effective in 69.6% (71/102) of the NACT group. The rate of metastasis in the NACT group (20.6%; 21/102) was significantly lower than the control group (42.2%; 35/83). The level of caspase-3 immunostaining and the rate of apoptosis in primary tumours and pelvic lymph nodes in the NACT group were significantly higher than in the control group.
NACT appeared to limit pelvic node metastasis by inducing tumour cell apoptosis in patients with cervical cancer.
探讨新辅助化疗(NACT)通过诱导宫颈癌患者肿瘤细胞凋亡是否能降低盆腔淋巴结转移。
本研究纳入了Ib2-IIb期宫颈癌患者,这些患者接受了基于顺铂的化疗(NACT组)或未接受化疗(对照组)后进行手术。采用半胱天冬酶-3免疫组织化学染色和原位末端脱氧核苷酸转移酶介导的脱氧尿苷三磷酸缺口末端标记法来测量原发性肿瘤和盆腔淋巴结中的凋亡水平。
共有185名患者参与研究:NACT组102例,对照组83例。NACT组69.6%(71/102)的患者治疗被认为临床有效。NACT组的转移率(20.6%;21/102)显著低于对照组(42.2%;35/83)。NACT组原发性肿瘤和盆腔淋巴结中的半胱天冬酶-3免疫染色水平和凋亡率显著高于对照组。
NACT似乎通过诱导宫颈癌患者肿瘤细胞凋亡来限制盆腔淋巴结转移。